Drugs / Recombinant Hepatitis B Virus Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02003703 | May 2015 → Jun 2018 | HIV infectious disease, hepatitis B virus infection | Universidad de Valparaiso | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Hepatitis B Virus Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02003703 ↗ |
| Known as | Engerix-B (R) | “Patients allocated to this arm will receive three doses of 40mcg each of recombinant hepatitis B vaccine (Engerix-B (R)). Doses will be administered at 0, 1 and 2 months.” NCT02003703 ↗ |
| Modality | Vaccine | “The high-dose HBV vaccination group consisted of 3 doses of 40 μg recombinant hepatitis B vaccine at 0, 1, and 2 months.” PMID 34424307 ↗ Aug 2021 |